Acolbifene/prasterone

Last updated
Acolbifene/prasterone
Combination of
Acolbifene Selective estrogen receptor modulator
Prasterone Androgen
Clinical data
Trade names Femivia (tentative)
Other namesPrasterone/acolbifene; Acolbifene/DHEA; DHEA/Acolbifene
Routes of
administration 		By mouth

Acolbifene/prasterone (tentative brand name Femivia) is a combination formulation of acolbifene, a selective estrogen receptor modulator, and prasterone (dehydroepiandrosterone; DHEA), an androgen, estrogen, and neurosteroid, which is under development by Endoceutics for the treatment of vasomotor symptoms (hot flashes) in postmenopausal women. [1] The formulation is intended for use by mouth. [1] As of December 2017, it is in phase III clinical trials for this indication. [1]

Contents

See also

References

  1. 1 2 3 "Acolbifene/Prasterone - Endoceutics - AdisInsight".


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.